Stay updated with breaking news from Priority Bacterial Pathogens. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil , a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal...
Intravacc secures $633K funding from CARB-X to develop a vaccine against or Neisseria gonorrhoeae....
/PRNewswire/ -- The Novo Nordisk Foundation is committing up to USD 25 million to support the early-stage development of innovative tools to prevent, diagnose...
/PRNewswire/ -- Day Zero Diagnostics Inc., an infectious disease diagnostics company utilizing genome sequencing and machine learning to combat the rise of...